Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
复制标题
DOI：
10.1016/j.bbmt.2013.08.012
复制
发表时间：
2014-01
影响因子：
4.3
通讯作者：
Schmid, Christoph
中科院分区：
文献类型：
--
作者：
de Lima, Marcos;Porter, David L.;Battiwalla, Minoo;Bishop, Michael R.;Giralt, Sergio A.;Hardy, Nancy M.;Kroeger, Nicolaus;Wayne, Alan S.;Schmid, Christoph
在关于造血干细胞移植后复发的生物学、预防和治疗的第二届NCI研讨会上，关于异基因移植后复发的预防和治疗的科学/教育会议强调了自第一届复发研讨会以来开发新治疗方法的进展。强调了可能为开发新型实用临床试验提供基础的最新见解，包括使用更新的药物，优化供体淋巴细胞输注（DLI）以及研究新型细胞疗法。德利马博士讨论了预防移植后复发的先发制人和维持策略，例如，最近有希望的结果表明低甲基化剂增强的移植物抗肿瘤活性。Schmid博士概述了改善复发细胞治疗的预防策略，包括DLI前的细胞减灭术、靶向药物与DLI的联合应用以及使用第二次移植的考虑因素。Porter博士阐述了增强T细胞功能的策略，包括离体活化T细胞和T细胞工程，以及增强体内T细胞功能的免疫调节方法，包括外源性细胞因子和共刺激途径的调节。
In the 2nd NCI Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Prevention and Treatment of Relapse after Allogeneic Transplantation highlighted progress in developing new therapeutic approaches since the 1st Relapse Workshop. Recent insights that might provide a basis for the development of novel, practical clinical trials were emphasized, including utilization of newer agents, optimization of donor lymphocyte infusion (DLI), and investigation of novel cellular therapies. Dr. de Lima discussed preemptive and maintenance strategies to prevent relapse after transplantation, e.g., recent promising results suggestive of enhanced graft-versus-tumor activity with hypomethylating agents. Dr. Schmid provided an overview of adjunctive strategies to improve cell therapy for relapse, including cytoreduction prior to DLI, combination of targeted agents with DLI, and considerations in use of second transplants. Dr. Porter addressed strategies to enhance T-cell function, including ex-vivo activated T cells and T-cell engineering, and immunomodulatory approaches to enhance T-cell function in vivo, including exogenous cytokines and modulation of costimulatory pathways.
登录
查看更多内容
影响因子：
20.3
作者：
Goodyear, Oliver C.;Dennis, Mike;Craddock, Charles F.
通讯作者：
Craddock, Charles F.
影响因子：
3.2
作者：
Falkenburg, JHF;Marijt, WAF;Willemze, R
通讯作者：
Willemze, R
影响因子：
20.3
作者：
Goodyear, Oliver;Agathanggelou, Angelo;Craddock, Charles
通讯作者：
Craddock, Charles
影响因子：
56.9
作者：
Bargou, Ralf;Leo, Eugen;Kufer, Peter
通讯作者：
Kufer, Peter
影响因子：
4.3
作者：
Alyea, Edwin P.;DeAngelo, Daniel J.;Moldrem, Jeffrey;Pagel, John M.;Przepiorka, Donna;Sadelin, Michel;Young, James W.;Giralt, Sergio;Bishop, Michael;Riddell, Stan
通讯作者：
Riddell, Stan